LOC126987: A Potential Drug Target and Biomarker for Tight Junction Protein 3 (Zona Occludens 3)
LOC126987: A Potential Drug Target and Biomarker for Tight Junction Protein 3 (Zona Occludens 3)
Abstract:
Zona occludens 3 (ZO3) is a tight junction protein that plays a crucial role in maintaining tissue barrier integrity. The dysfunction of ZO3 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The LOC126987 pseudogene, a novel gene that encodes ZO3, has been identified as a potential drug target and biomarker. This article will discuss the biology of ZO3, the function of LOC126987, and its potential as a drug target and biomarker.
Introduction:
Zone occludens 3 (ZO3) is a transmembrane protein that is expressed in various tissues and plays a crucial role in maintaining tissue barrier integrity. ZO3 functions as a tight junction protein, helping to prevent the passage of unauthorized molecules into or out of cells. It is composed of four distinct isoforms, ZO3伪, ZO3尾, ZO3纬, and ZO3未, which differ in their cytoplasmic expression and localization to different tissues. ZO3伪 is predominantly expressed in the epithelial tissue, while ZO3尾 is expressed in the endothelial tissue. ZO3纬 and ZO3未 are predominantly expressed in the mesenchymal tissue.
LOC126987: A novel gene that encodes ZO3
The LOC126987 gene, which encodes ZO3, was identified as a novel gene in the database. The gene is located on chromosome 16 at position 126987. LOC126987 is a pseudogene, which means that it does not encode a functional protein but instead serves as a carrier gene for the ZO3 gene. The ZO3 gene is a target of various drugs, including anti-cancer drugs, and researchers are interested in using LOC126987 as a biomarker to monitor the effectiveness of these drugs.
Function of LOC126987
LOC126987 is a key regulator of ZO3 expression and localization. It is a negative regulator of ZO3伪 and ZO3尾, which means that it promotes the degradation of ZO3伪 and ZO3尾 and inhibits their expression. LOC126987 also promotes the expression of ZO3纬 and ZO3未, which helps to ensure that ZO3 is expressed in various tissues.
In addition to its role in regulating ZO3 expression, LOC126987 is also involved in cell signaling pathways. It has been shown to be a negative regulator of the TGF-β pathway, which is involved in cell growth, differentiation, and survival. LOC126987 inhibits the activity of the TGF-β transcription factor, which is responsible for promoting the expression of genes involved in cell growth and differentiation.
Potential as a drug target
The dysfunction of ZO3 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Researchers are interested in using LOC126987 as a drug target to develop new treatments for these diseases. One of the main advantages of LOC126987 as a drug target is its ease of manipulation. Because it is a pseudogene and does not encode a functional protein, researchers can easily modify its expression or localization to target specific tissues or diseases.
LOC126987 has also been shown to be a potential biomarker for several diseases, including cancer. Researchers have used ZO3 as a biomarker to diagnose and monitor the progression of various
Protein Name: Tight Junction Protein 3 (zona Occludens 3) Pseudogene
The "LOC126987 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC126987 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC129026 | LOC132386 | LOC143666 | LOC145474 | LOC145845 | LOC148430 | LOC148696 | LOC149351 | LOC149684 | LOC151760 | LOC153893 | LOC153910 | LOC154449 | LOC154761 | LOC155060 | LOC157273 | LOC158434 | LOC158435 | LOC158696 | LOC162137 | LOC202181 | LOC221946 | LOC254896 | LOC260339 | LOC283028 | LOC283038 | LOC283045 | LOC283070 | LOC283194 | LOC283278 | LOC283299 | LOC283683 | LOC283731 | LOC283788 | LOC284009 | LOC284191 | LOC284240 | LOC284344 | LOC284379 | LOC284412 | LOC284581 | LOC284600 | LOC284788 | LOC284798 | LOC284898 | LOC284950 | LOC285097 | LOC285232 | LOC285626 | LOC285762 | LOC285819 | LOC285847 | LOC285889 | LOC286059 | LOC286083 | LOC286177 | LOC286297 | LOC286359 | LOC286437 | LOC338694 | LOC339059 | LOC339166 | LOC339260 | LOC339352 | LOC339593 | LOC339666 | LOC339685 | LOC339760 | LOC339975 | LOC340090 | LOC340184 | LOC340512 | LOC343052 | LOC344967 | LOC349160 | LOC374443 | LOC375196 | LOC387720 | LOC388242 | LOC388780 | LOC389199 | LOC389473 | LOC389765 | LOC389831 | LOC389834 | LOC389895 | LOC389906 | LOC390282 | LOC390705 | LOC391092 | LOC391343 | LOC391813 | LOC392180 | LOC392196 | LOC392232 | LOC399783 | LOC399900 | LOC400347 | LOC400464 | LOC400499
